Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 5/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819527 | 0.89 | CYP11B2 (0.36) | MAPK1CYP11B2CYP11B1IDO1TRPA1 | |
| SCHEMBL2819615 | 0.82 | CYP11B2 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL2817700 | 0.81 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL9493247 | 0.81 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL9493435 | 0.81 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL2817853 | 0.80 | SLC6A2 (0.41) | MAPK1CYP11B2CYP11B1IDO1 | |
| SCHEMBL10387923 | 0.79 | MAPK1 (0.40) | MAPK1CYP11B2CYP11B1IDO1KDM4E | |
| SCHEMBL10387985 | 0.78 | CYP11B2 (0.45) | MAPK1CYP11B2CYP11B1IDO1KDM4E | |
| SCHEMBL2817737 | 0.77 | CYP11B2 (0.30) | CYP11B2IDO1 | |
| SCHEMBL3190003 | 0.75 | MAPK1 (0.47) | MAPK1CYP11B2CYP11B1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | MAPK1 977/4885CYP11B2 6/4885CYP11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.